Preoperative Combination Therapy with Camrelizumab, Paclitaxel, and Nedaplatin for Unresectable Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase 2 Trial - Summary - MDSpire

Preoperative Combination Therapy with Camrelizumab, Paclitaxel, and Nedaplatin for Unresectable Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase 2 Trial

  • By

  • Jinhong Zhu

  • Jinfeng Zhang

  • Xiaodong Ling

  • Changhong Wang

  • Yingnan Yang

  • Yangzhong Xin

  • Hao Jiang

  • Hao Liang

  • Luquan Zhang

  • Xionghai Qin

  • Jingle Lei

  • Chengyuan Fang

  • Xinxin Yang

  • Yuning Wang

  • Wei Meng

  • Xiaoyuan Wang

  • Hongxue Meng

  • Jianqun Ma

  • December 28, 2025

  • 0 min

Share

Objective:

To evaluate the efficacy and safety of preoperative camrelizumab combined with paclitaxel and nedaplatin as conversion therapy for patients with unresectable esophageal squamous cell carcinoma (ESCC).

Key Findings:
  • The combination therapy demonstrated a significant conversion rate to operability in patients with initially unresectable ESCC.
  • High rates of pathological complete response (pCR) and major pathological response (MPR) were observed.
  • The safety profile was consistent with previous studies, with manageable adverse events.
Interpretation:

The results suggest that camrelizumab combined with chemotherapy may effectively downstage unresectable ESCC, potentially allowing for curative surgical intervention.

Limitations:
  • Single-arm design limits generalizability of results.
  • Lack of a control group for comparative analysis.
Conclusion:

Preoperative combination therapy with camrelizumab, paclitaxel, and nedaplatin shows promise as a conversion strategy for unresectable ESCC, warranting further investigation in larger trials.

Original Source(s)

Preoperative Combination Therapy with Camrelizumab, Paclitaxel, and Nedaplatin for Unresectable Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase 2 Trial

  • by Jinhong Zhu, Jinfeng Zhang, Xiaodong Ling, Changhong Wang, Yingnan Yang, Yangzhong Xin, Hao Jiang, Hao Liang, Luquan Zhang, Xionghai Qin, Jingle Lei, Chengyuan Fang, Xinxin Yang, Yuning Wang, Wei Meng, Xiaoyuan Wang, Hongxue Meng, Jianqun Ma

  • December 28, 2025

Related Content

Dose-dependent tuning of HSP70–Beclin-1 by kaempferol governs autophagy and chemosensitivity

Dual-energy and perfusion CT for predicting response to chemo-radiotherapy in head and neck cancer: an exploratory study

Case Report: Long-term survival in advanced PD-L1-high squamous cell lung cancer following severe immune-related cardiotoxicity